Speaker: Robert C. Tasker, MBBS, MD, MA, FRCP, RCPCH
Robert C. Tasker, MBBS, MD, MA, FRCP, RCPCH: Welcome. My name is Robert Tasker and I'm your Editor-in-Chief of Pediatric Critical Care Medicine. July 2024, a special month for us. This is 25 years since the journal first started. As a celebration of that, Pat Kochanek and I have written a foreword about the journal and its evolution. We provide an overview of the four themes of clinical research that's in our portfolio. Please look at this and consider the landscape in which PCCM fits. I'm pleased to announce as well that PCCM has hit new heights with an impact factor of 4.0. My three editors choices are first, oxygen exposure and the brain in neonates on ECMO. This is an ELSO data set study 2015 to 2020. 3,500 newborns, lead author Brohan et al and look at the "U-shaped" curve in terms of exposure and outcomes. The second editor's choice is about PARDS risk stratification using biomarkers. This is a data set from 2014 to 2019, single center with Whitney et al our as the authors. The third editor's choice is respiratory bacterial code detection in under two-year-olds who are mechanically ventilated for bronchiolitis. This is the BACON study which is a collaborative of the Latin America, LARed network and the PALISI network. This paper deals with 470 plus patients and the lead author is Karsies and we hope to see more material from this study. The PCCM Connection section is an educational section and this time it's given over to anticoagulation management during ECMO. We're pleased to to present the PEACE consensus which covers literature from 1988 through 2021, eight subject subgroups, 23 recommendations, 52 consensus statements, 16 good practice statements, beautifully illustrated, lead author Alexander. There is an accompanying editorial. In the PCCM International section. we've got lots of international content, but I'd just like to focus on the trials. First, there's a protocol from the UK Pediatric Critical Care Society study group describing the pressure trial. This is blood pressure targeting. The other trials content is a pro con debate about the Oxy-PICU study or the oxygen targeting study that was published in the Lancet in 2024 in January. There's a critique by two trialists from Switzerland and Australia. and we have a response from the trial investigators talking through some of the questions and issues that were raised. Lastly, I just want to draw your attention to a reflection on the compendium of narrative material that we have published from 2021 through to 2024. Wynne Morrison and Daniel DeCourcey have written this and the purpose of it is to enable you to have a place where you get ready access to all the material. So, all in all a great celebratory journal for our 25th year. Thank you very much for all of your support and I will see you next month. Thank you.
